Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma

About this update from Beijing Konruns Pharmaceutical Co., Ltd. Class A

Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Konruns Pharmaceutical Co., Ltd. Class A